DTU Logo
About the DTU | News | Staff | Alumni | Contact/Find us | Job opportunities

News


Search news :

TECOS Update

02-Aug-2010
News Image Since the first subject was enrolled in December 2008, TECOS has witnessed a number of study milestones. The majority of sites are now actively enrolling patients....

[Read more...]

ACE is seeking ancillary study proposals...

22-Jul-2010
News Image

[Link]

NAVIGATOR trial results published

15-Mar-2010
News Image NAVIGATOR was presented as a Late Breaking Clinical Trial on March 14, 2010, at the American College of Cardiology's Scientific Sessions in Atlanta, Georgia. The trial was concurrently published as two publications in the New England Journal of Medicine.

[Link]

NAVIGATOR valsartan results presented at ACC.10 in Atlanta

14-Mar-2010
News Image Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events
The NAVIGATOR Study Group
N Engl J Med 2010 on-line (10.1056/NEJMoa1001121)

Background
It is not known whether drugs that block the renin-angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance.

Methods
In this double-blind, randomized clinical trial with a 2-by-2 factorial design, we assigned 9306 patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) or placebo (and nateglinide or placebo) in addition to lifestyle modification....

[Read more...]

NAVIGATOR nateglinide results presented at ACC.10 in Atlanta

14-Mar-2010
News Image Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events
The NAVIGATOR Study Group
N Engl J Med 2010 on-line (10.1056/NEJMoa1001122)

Background
The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown.

Methods
In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors to receive nateglinide (up to 60 mg three times daily) or placebo, in a 2-by-2 factorial design with valsartan or placebo, in addition to participation in a lifestyle modification program....

[Read more...]

NAVIGATOR results slide set

14-Mar-2010
News Image Download a slide deck showing the primary NAVIGATOR results of the effects of nateglinide and valsartan on the incidence of diabetes and cardiovascular events by clicking on the link below.



[Link]

NAVIGATOR Baseline paper published

02-Mar-2010
News Image Baseline Characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Population: Comparison with Other Diabetes Prevention Trials
Henry Krum, John J.V....

[Read more...]

Personal Chair awarded to Dr Andrew Farmer

02-Feb-2010
News Image Congratulations to Andrew who has been awarded the title of Professor of General Practice with immediate effect by the University's Recognition of Distinction Committee